Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Smits

Showing results (261-270 of 295) with videos related to

Pageof 30
Sort By:
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 1, 2013
The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trialsBill D Gogas, Christos V Bourantas, Hector M Garcia-Garcia, et al.
Circulation|August 11, 2017
Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: Primary Results From the BIONICS Trial (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis)David E Kandzari, Pieter C Smits, Michael P Love, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 16, 2026
Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: final 7-year results of the COMPARE-ABSORB trialPieter C Smits, Adrian Włodarczak, Bernard Chevalier, et al.
European Heart Journal|May 17, 2022
Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysisMarco Valgimigli, Pieter C Smits, Enrico Frigoli, et al.
Circulation|April 6, 2021
Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical TrialAlexandra J Lansky, Dean J Kereiakes, Andreas Baumbach, et al.
Journal of the American College of Cardiology|August 18, 2022
Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet TherapyMarco Valgimigli, Enrico Frigoli, Pascal Vranckx, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|May 24, 2024
Frequency of periprocedural myocardial injury and infarction stratified by cardiac troponin I and cardiac troponin TPruthvi C Revaiah, Tsung-Ying Tsai, Bo Wang, et al.
JACC. Cardiovascular Interventions|June 23, 2012
Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trialBill D Gogas, Patrick W Serruys, Roberto Diletti, et al.
JACC. Cardiovascular Interventions|December 24, 2011
Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trialSalvatore Brugaletta, Josep Gomez-Lara, Patrick W Serruys, et al.
Journal of the Society for Cardiovascular Angiography & Interventions|August 12, 2024
Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III SubstudyKush P Patel, Alexandra J Lansky, Dean J Kereiakes, et al.
Pageof 30

Showing results (261-270 of 295) with videos related to

Sort By:
Pageof 30
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 1, 2013
The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trialsBill D Gogas, Christos V Bourantas, Hector M Garcia-Garcia, et al.
Circulation|August 11, 2017
Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: Primary Results From the BIONICS Trial (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis)David E Kandzari, Pieter C Smits, Michael P Love, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 16, 2026
Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: final 7-year results of the COMPARE-ABSORB trialPieter C Smits, Adrian Włodarczak, Bernard Chevalier, et al.
European Heart Journal|May 17, 2022
Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysisMarco Valgimigli, Pieter C Smits, Enrico Frigoli, et al.
Circulation|April 6, 2021
Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical TrialAlexandra J Lansky, Dean J Kereiakes, Andreas Baumbach, et al.
Journal of the American College of Cardiology|August 18, 2022
Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet TherapyMarco Valgimigli, Enrico Frigoli, Pascal Vranckx, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|May 24, 2024
Frequency of periprocedural myocardial injury and infarction stratified by cardiac troponin I and cardiac troponin TPruthvi C Revaiah, Tsung-Ying Tsai, Bo Wang, et al.
JACC. Cardiovascular Interventions|June 23, 2012
Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trialBill D Gogas, Patrick W Serruys, Roberto Diletti, et al.
JACC. Cardiovascular Interventions|December 24, 2011
Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trialSalvatore Brugaletta, Josep Gomez-Lara, Patrick W Serruys, et al.
Journal of the Society for Cardiovascular Angiography & Interventions|August 12, 2024
Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III SubstudyKush P Patel, Alexandra J Lansky, Dean J Kereiakes, et al.
Pageof 30